Extrait

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Critère d'inclusion

• Chronic lymphocytic leukemia ,Small Lymphocytic Lymphoma

Pays

• Australia
• China
• Malaysia
• Taiwan, Province of China

Liens

• ictrp
• nct